## AMENDMENTS TO THE CLAIMS

Listing of Claims:

1. (Original) A storage stable pharmaceutical preparation comprising oxycodone and naloxone in a substantially non-swellable diffusion matrix comprising ethyl cellulose, characterized in that the active compounds are released from the preparation in a sustained, invariant and independent manner.

2. (Original) Preparation according to claim 1, characterized in that oxycodone and/or naloxone are present in the form of pharmaceutically acceptable and equally active derivatives such as the free base, salts and the like.

3. (Currently Amended) Preparation according to claim 2, characterized in that [that] oxycodone and/or naloxone are present as their hydrochloride, sulfate, bisulfate, tatrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate.

4. (Currently Amended) Preparation according to claim 3 [one of the preceding claims], characterized in that oxycodone is present in excess referred to the unit dosage amount of naloxone.

5. (Currently Amended) Preparation according to claim 1 [one of the preceding claims], characterized in that naloxone is present in an amount range of about 1 mg to about 50 mg.

6. (Currently Amended) Preparation according to claim 1 [one of the preceding claims], characterized in that oxycodone is present in an amount range of about 10 mg to about 150 mg [, preferably of 10 to 80 mg].

7. (Currently Amended) Preparation according to claim 1 [one of the preceding claims], characterized in that oxycodone and naloxone are present in weight ratio ranges of from about [maximal] 25:1 [,] to about [preferably of maximal 20:1, 15:1, especially preferably of 5:1, 4:1, 3:1, 2:1 or] 1:1.

8. (Currently Amended) Preparation according to claim 7 [one of the preceding claims], characterized in that the preparation comprises a substantially non-erosive diffusion matrix.

9. (Currently Amended) Preparation according to claim [1 or] 8, characterized in that the diffusion matrix comprises at least ethylcellulose and at least one fatty alcohol as the components that essentially influence the release behavior of the active compounds.

10. (Currently Amended) Preparation according to claim [1, 8 or] 9, characterized in that the preparation does not comprise relevant parts of alkaline and/or water-swellable substance, [especially of derivatives of acrylic acid and/or hydroxy alkyl celluloses].

11. (Currently Amended) Preparation according to claim 10 [one of the preceding claims], characterized in that the preparation contains [usual] fillers and additional substances[, especially lubricants, flowing agents, plasticizers and the like].

12. (Currently Amended) Preparation according to claim 11, characterized in that it comprises magnesium stearate, calcium stearate and/or calcium laureate and/or fatty acids[, preferably stearic acid as the lubricant].

13. (Currently Amended) Preparation according to claim11, characterized in that it comprises a flowing agent selected from the group consisting of highly-disperse silica, [preferably Aerosil®, Talcum], talcum, corn starch, magnesium oxide and magnesium and[/or] calcium stearate [as the flowing agent].

14. (Currently Amended) A storage stable pharmaceutical preparation comprising oxycodone and naloxone in a substantially non-swellable diffusion matrix, characterized in that the matrix is influenced with respect to its substantial release characteristics by ethylcellulose and at lease one fatty alcohol and that the preparation comprises oxycodone and naloxone in a weight ratio of from about [maximal] 25:1 to about [preferably, maximal 20:1, 15:1, especially preferably of 5:1, 4:1, 3:1, 2:1 or] 1:1.

15. (Currently Amended) Preparation according to claim 14, characterized in that the oxycodone and naloxone are present in the form of pharmaceutically acceptable and equally active derivatives[, such as the free-base, salts and the like].

16. (Original) Preparation according to claim 15, characterized in that oxycodone and naloxone are present as hydrochloride, sulfate, bisulfate, tatrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate or succinate.

17. (Currently Amended) Preparation according to [one of claims 14 to] claim 16, characterized in that oxycodone is present in excess referred to the unit dosage amount of naloxone.

18. (Currently Amended) Preparation according to [one of claims 14 to] claim 17, characterized in that oxycodone is present in an amount range of about 1 mg to about 50 mg.

19. (Currently Amended) Preparation according to [one of claims 14 to] claim 18, characterized in that oxycodone is present in an amount range of about 10 mg to about 150 mg[ , preferably of 10 to 80 mg].

20. (Currently Amended) Preparation according to [one of claims 14 to] claim 19, characterized in that preparation comprises a substantially non-swellable and non-erosive diffusion matrix.

21. (Original) Preparation according to claim 20, characterized in that the diffusion matrix comprises at least ethylcellulose and at least one fatty alcohol as the components that essentially influence the release behavior of the active compounds.

22. (Currently Amended) Preparation according to claim [20 or] 21, characterized in that the preparation does not comprise relevant parts of alkaline and/or water-swellable substance[, especially of derivatives of acrylic acid and/or hydroxy alkyl celluloses].

23. (Currently Amended) Preparation according to [one of claims 14 to] claim 22, characterized in that the fatty alcohols comprise lauryl, myrestyl, stearyl, cetostearyl, ceryl and/or cetyl alcohol[, especially preferably stearyl alcohol].

24. (Currently Amended) Preparation according to [one of claims 14 to] claim 23, characterized in that the preparation comprises [usual] fillers and additional substances[, especially lubricants, flowing agents, plasticizers and the like].

25. (Currently Amended) Preparation according to claim 24, characterized in that it comprises magnesium stearate, calcium stearate and/or calcium laureate and/or fatty acids[, preferably stearic acid as lubricant].

26. (Currently Amended) Preparation according to claim 24, characterized in that it comprises a flowing agent selected from the group consisting of highly-disperse silica, [preferably Aerosil®,] talcum, corn starch, magnesium oxide, magnesium stearate and[/or] calcium stearate [as flowing agent].

27. (Currently Amended) Preparation according to [one of the preceding claims] claim 26, characterized in that commercially available polymer mixtures which comprise ethylcellulose[, preferably Surelease® E-7-7050] are used instead of ethylcellulose.

28. (Currently Amended) Preparation according to [one of the preceding claims] claim 27, characterized in that the preparation has been formulated for oral, nasal, rectal application or for application by inhalation.

29. (Currently Amended) Preparation according to [one of the preceding claims] claim 28, characterized in that the preparation is in the form of a tablet, pill, capsule, granule [and/]or powder.

30. (Currently Amended) Preparation according to [one of the preceding claims] claim 29, characterized in that preparation or precursors thereof are produced by build-up and/or break-down granulation.

31. (Currently Amended) Preparation according to [one of claims 1 to] claim 29, characterized in that the preparation or precursors thereof are produced by extrusion.

32. (Currently Amended) Preparation according to [one of the preceding claims] claim 31, characterized in that the preparation can be stored over a period of at least 2 years under standard conditions (60% relatively humidity, 25°C) in accordance with admission guidelines.

33. (New) A preparation according to claim 6, characterized in that oxycodone is present in an amount range of from about 10 mg to about 80 mg.

34. (New) A preparation according to claim 7, characterized in that oxycodone and naloxone are present in weight ratio ranges of from about 5:1 to about 1:1.

35. (New) A preparation according to claim 10, characterized in that the preparation does not comprise relevant parts of derivatives of acrylic acid and/or hydroxy alkyl celluloses.

36. (New) A preparation according to claim 11, further comprising one or more materials from the group consisting of lubricants, flowing agents, plasticizers and the like.

37. (New) A preparation according to claim 12, characterized in that it comprises stearic acid.

38. (New) A storage stable pharmaceutical preparation according to claim 14, comprising oxycodone and naloxone in a substantially non-swellable diffusion matrix, characterized in that the matrix is influenced with respect to its substantial release characteristics by ethylcellulose and at lease one fatty alcohol and that the preparation comprises oxycodone and naloxone in a weight ratio of from about 5:1 to about 1:1.

39. (New) A preparation according to claim 19, characterized in that oxycodone is present in an amount range of about 10 mg to about 80 mg.

40. (New) A preparation according to claim 22, characterized in that the preparation does not comprise relevant parts of derivatives of acrylic acid and/or hydroxy alkyl celluloses.

41. (New) A preparation according to claim 24, further comprising one or more materials from the group consisting of lubricants, flowing agents, plasticizers and the like.

42. (New) A preparation according to claim 25, characterized in that it comprises stearic acid.

43. (New) A preparation according to claim 27, characterized in that the commercially available polymer mixture is Surelease® E-7-7050.

44. (New) A preparation according to claim 15, characterized in that the pharmaceutically acceptable and equally active derivatives are the free-base, salts and the like.